Leukocyte etravasation as a target for anti-inflammatory therapy - Which molecule to choose?

Wolf Henning Boehncke, Michael P. Schön, Giampiero Giromolomi, Jan D. Bos, Kristian Thestrup-Pedersen, Andrea Cavani, Frank O. Nestle, Brian K. Bonish, James J. Campbell, Brian J. Nickoloff

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

In view of the central pathogenic importance of leukocyte extravasation in inflammatory skin diseases, therapeutic interference with this - surprisingly complex - process is clearly a promising new approach for treating these dermatoses. Despite some disappointments during the clinical use of these agents and despite their crippling price tag, the recent incorporation of biologicals that target defined molecular controls of leukocyte extravasation into dermatological and rheumatological practise, consequently, has greatly enriched our therapeutic options for battling major, chronic, inflammatory dermatoses such as psoriasis. However, the - as yet unresolved and still rather controversially discussed - critical question is: Which of the multiple steps that control leukocyte extravasation in the human system really offer the most promising, most pragmatic, and safest molecular targets for therapeutic intervention for which disease entity? The current debate intends to stimulate public and rational debate of this crucial issue, beyond the evident commercial interests that are touched by whatever stand one takes.

Original languageEnglish
Pages (from-to)70-80
Number of pages11
JournalExperimental Dermatology
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Skin Diseases
Leukocytes
Anti-Inflammatory Agents
Molecules
Skin
Psoriasis
Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

Boehncke, W. H., Schön, M. P., Giromolomi, G., Bos, J. D., Thestrup-Pedersen, K., Cavani, A., ... Nickoloff, B. J. (2005). Leukocyte etravasation as a target for anti-inflammatory therapy - Which molecule to choose? Experimental Dermatology, 14(1), 70-80. https://doi.org/10.1111/j.0906-6705.2005.290b.x

Leukocyte etravasation as a target for anti-inflammatory therapy - Which molecule to choose? / Boehncke, Wolf Henning; Schön, Michael P.; Giromolomi, Giampiero; Bos, Jan D.; Thestrup-Pedersen, Kristian; Cavani, Andrea; Nestle, Frank O.; Bonish, Brian K.; Campbell, James J.; Nickoloff, Brian J.

In: Experimental Dermatology, Vol. 14, No. 1, 01.2005, p. 70-80.

Research output: Contribution to journalArticle

Boehncke, WH, Schön, MP, Giromolomi, G, Bos, JD, Thestrup-Pedersen, K, Cavani, A, Nestle, FO, Bonish, BK, Campbell, JJ & Nickoloff, BJ 2005, 'Leukocyte etravasation as a target for anti-inflammatory therapy - Which molecule to choose?', Experimental Dermatology, vol. 14, no. 1, pp. 70-80. https://doi.org/10.1111/j.0906-6705.2005.290b.x
Boehncke, Wolf Henning ; Schön, Michael P. ; Giromolomi, Giampiero ; Bos, Jan D. ; Thestrup-Pedersen, Kristian ; Cavani, Andrea ; Nestle, Frank O. ; Bonish, Brian K. ; Campbell, James J. ; Nickoloff, Brian J. / Leukocyte etravasation as a target for anti-inflammatory therapy - Which molecule to choose?. In: Experimental Dermatology. 2005 ; Vol. 14, No. 1. pp. 70-80.
@article{3ef1ca81416c44cbbebeefc008465a2d,
title = "Leukocyte etravasation as a target for anti-inflammatory therapy - Which molecule to choose?",
abstract = "In view of the central pathogenic importance of leukocyte extravasation in inflammatory skin diseases, therapeutic interference with this - surprisingly complex - process is clearly a promising new approach for treating these dermatoses. Despite some disappointments during the clinical use of these agents and despite their crippling price tag, the recent incorporation of biologicals that target defined molecular controls of leukocyte extravasation into dermatological and rheumatological practise, consequently, has greatly enriched our therapeutic options for battling major, chronic, inflammatory dermatoses such as psoriasis. However, the - as yet unresolved and still rather controversially discussed - critical question is: Which of the multiple steps that control leukocyte extravasation in the human system really offer the most promising, most pragmatic, and safest molecular targets for therapeutic intervention for which disease entity? The current debate intends to stimulate public and rational debate of this crucial issue, beyond the evident commercial interests that are touched by whatever stand one takes.",
author = "Boehncke, {Wolf Henning} and Sch{\"o}n, {Michael P.} and Giampiero Giromolomi and Bos, {Jan D.} and Kristian Thestrup-Pedersen and Andrea Cavani and Nestle, {Frank O.} and Bonish, {Brian K.} and Campbell, {James J.} and Nickoloff, {Brian J.}",
year = "2005",
month = "1",
doi = "10.1111/j.0906-6705.2005.290b.x",
language = "English",
volume = "14",
pages = "70--80",
journal = "Experimental Dermatology",
issn = "0906-6705",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Leukocyte etravasation as a target for anti-inflammatory therapy - Which molecule to choose?

AU - Boehncke, Wolf Henning

AU - Schön, Michael P.

AU - Giromolomi, Giampiero

AU - Bos, Jan D.

AU - Thestrup-Pedersen, Kristian

AU - Cavani, Andrea

AU - Nestle, Frank O.

AU - Bonish, Brian K.

AU - Campbell, James J.

AU - Nickoloff, Brian J.

PY - 2005/1

Y1 - 2005/1

N2 - In view of the central pathogenic importance of leukocyte extravasation in inflammatory skin diseases, therapeutic interference with this - surprisingly complex - process is clearly a promising new approach for treating these dermatoses. Despite some disappointments during the clinical use of these agents and despite their crippling price tag, the recent incorporation of biologicals that target defined molecular controls of leukocyte extravasation into dermatological and rheumatological practise, consequently, has greatly enriched our therapeutic options for battling major, chronic, inflammatory dermatoses such as psoriasis. However, the - as yet unresolved and still rather controversially discussed - critical question is: Which of the multiple steps that control leukocyte extravasation in the human system really offer the most promising, most pragmatic, and safest molecular targets for therapeutic intervention for which disease entity? The current debate intends to stimulate public and rational debate of this crucial issue, beyond the evident commercial interests that are touched by whatever stand one takes.

AB - In view of the central pathogenic importance of leukocyte extravasation in inflammatory skin diseases, therapeutic interference with this - surprisingly complex - process is clearly a promising new approach for treating these dermatoses. Despite some disappointments during the clinical use of these agents and despite their crippling price tag, the recent incorporation of biologicals that target defined molecular controls of leukocyte extravasation into dermatological and rheumatological practise, consequently, has greatly enriched our therapeutic options for battling major, chronic, inflammatory dermatoses such as psoriasis. However, the - as yet unresolved and still rather controversially discussed - critical question is: Which of the multiple steps that control leukocyte extravasation in the human system really offer the most promising, most pragmatic, and safest molecular targets for therapeutic intervention for which disease entity? The current debate intends to stimulate public and rational debate of this crucial issue, beyond the evident commercial interests that are touched by whatever stand one takes.

UR - http://www.scopus.com/inward/record.url?scp=13844307727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844307727&partnerID=8YFLogxK

U2 - 10.1111/j.0906-6705.2005.290b.x

DO - 10.1111/j.0906-6705.2005.290b.x

M3 - Article

VL - 14

SP - 70

EP - 80

JO - Experimental Dermatology

JF - Experimental Dermatology

SN - 0906-6705

IS - 1

ER -